Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022191 · ClinicalTrials.gov registry record · Phase 3
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
A Phase 3 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- Completed
- Registry status
- Phase 3
- Development phase
- 608
- Enrollment target
NCT00022191 is a Phase 3 study that has completed, run by European Organisation for Research and Treatment of Cancer - EORTC. The registered enrollment target is 608 participants.
The verdict
NCT00022191, a Phase 3 study, has completed, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 608 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus gemcitabine with or without paclitaxel in treating patients who have stage IV urinary tract cancer.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2001-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022191
The ClinicalTrials.gov registry entry for NCT00022191 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 608 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00022191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00022191 about?
NCT00022191 is a clinical study titled "Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplati...
What is the current status of trial NCT00022191?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 608 participants. The study started on 2001-05.
What interventions are being tested in trial NCT00022191?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00022191?
This trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.